Clinical-stage Pharmaceutical Company Presents Positive Results From CNS Disorder Study
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model.
Disclaimer: The following article discusses a business announcement and is for informational purposes only. It should not be construed as financial advice. Always consult with a financial advisor before making any investment decisions.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NASDAQ: NLSPW), a Swiss clinical-stage biopharmaceutical company dedicated to therapies for rare and complex central nervous system disorders, has made a significant advancement in the treatment of narcolepsy. At the recent American Society of Clinical Psychopharmacology (ASCP) conference in Miami, NLS announced promising results from its preclinical study KO-874, which evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model.
The Study's Essence and Its Implications
The study focused on rats with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH). The findings offer hope for new therapies that address both sleep and wakefulness disorders. Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics, articulated the importance of these results: "These data underscore our continued commitment to advancing our pipeline, which has the potential to change the treatment paradigm for patients impacted by sleep and wakefulness disorders. This highlights the promise of mazindol to reduce the suffering of patients with narcolepsy."
Poster Presentation Overview
Title: Neuroprotective Effect of Mazindol on Nocturnal Activity in an Orexin-B-Saporin-Induced Narcoleptic-Like Model in Sprague-Dawley Rats
Presenter: Dr. Eric Konofal
Date and Time: Thursday, May 30, 2024, 12:30-2:15pm ET
Mazindol, administered at a dose of 3 mg/kg, significantly mitigated the reduction in circadian activity typically induced by OX-B-SAP lesions. By Day 21, mazindol not only restored activity levels to normal but exceeded those of the sham group during the dark phase, demonstrating a robust protective effect against orexin cell loss.
Dose-Dependent Response
The study emphasized the importance of dosage. Lower doses of mazindol (1 mg/kg) did not show therapeutic benefits and might have aggravated the decrease in activity between days 5 and 8 post-lesion. Conversely, the higher dose (3 mg/kg) significantly increased circadian activity, indicating its potential utility in treating disorders like narcolepsy, where disruption of the orexin system leads to decreased wakefulness.
Orexinergic Mechanisms
The results suggest that mazindol might exert its effects through direct or indirect modulation of orexin receptors or pathways influenced by the orexin system. The lack of significant modification in the number of orexin neurons by mazindol treatment underscores the complex interaction between mazindol and orexin signaling.
Study Details
The study utilized Sprague-Dawley rats with OX-B-SAP lesions in the LH to mimic narcoleptic symptoms. The primary objectives were to assess the extent of circadian activity disruption and evaluate the neuroprotective impact of mazindol. Key parameters included:
Circadian Activity Monitoring: Activity was recorded continuously, with significant findings showing that mazindol-treated rats exhibited higher activity levels during the dark phase compared to vehicle-treated rats.
Histological Analysis: The extent of orexin neuron loss was evaluated post-mortem, confirming the targeted lesioning by OX-B-SAP and the neuroprotective effect of mazindol.
The Role of Orexin in Sleep Disorders
Orexin (also known as hypocretin) is a neuropeptide that plays a crucial role in regulating arousal, wakefulness, and appetite. Narcolepsy, particularly Type 1, is characterized by a significant loss of orexin-producing neurons in the hypothalamus, leading to excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep.
Understanding Narcolepsy: Narcolepsy affects approximately 0.02%-0.05% of the population and often goes undiagnosed or misdiagnosed. Current treatments primarily focus on managing symptoms rather than addressing the underlying neuronal deficits. Consequently, there is a substantial unmet need for therapies that can restore normal orexin function or protect orexin neurons from degeneration.
Mazindol: A Potential Game-Changer: Mazindol, a tetracyclic compound, has been historically used as an anorectic agent. However, recent studies have explored its potential neuroprotective and wake-promoting effects. The ability of mazindol to enhance circadian activity and possibly interact with orexin pathways presents a novel approach to treating narcolepsy and related disorders.
Future Research and Development Steps: The positive outcomes from study KO-874 support further clinical development of mazindol as a potential therapeutic for narcolepsy and other disorders involving orexin system disruption. This breakthrough could pave the way for new treatments that significantly improve the quality of life for individuals suffering from these debilitating conditions.
Next Steps for NLS Pharmaceutics
NLS Pharmaceutics plans to advance mazindol into clinical trials, aiming to validate these preclinical findings in human subjects. This progression will involve:
Phase I Trials: Initial trials will focus on assessing the safety, tolerability, and pharmacokinetics of mazindol in healthy volunteers.
Phase II Trials: Subsequent trials will evaluate the efficacy and optimal dosing of mazindol in patients with narcolepsy.
Regulatory Engagement: Continuous dialogue with regulatory authorities such as the FDA and EMA to ensure compliance and expedite the development process.
This development aligns with NLS Pharmaceutics’ strategic vision of pioneering novel therapies for central nervous system disorders. The company’s focus on rare and complex conditions positions it uniquely in the biopharmaceutical landscape, potentially leading to significant advancements in treatment protocols and improved patient outcomes.
Investor Insights
The promising results from study KO-874 have several important implications for investors:
Potential Market Opportunity: Successful development and commercialization of mazindol could open substantial market opportunities, given the significant unmet needs in narcolepsy treatment.
Stock Performance: Positive preclinical and clinical trial results can drive investor confidence, potentially boosting stock performance.
Partnerships and Collaborations: Demonstrating mazindol's efficacy could attract strategic partnerships or licensing agreements, providing additional funding and resources for further development.
The promising results from NLS Pharmaceutics' preclinical study KO-874 highlight the potential of mazindol as a neuroprotective therapy for narcolepsy. These findings mark a significant milestone in the company's mission to develop innovative treatments for central nervous system disorders. As NLS Pharmaceutics advances mazindol into clinical trials, the potential for transforming the treatment landscape for narcolepsy and improving patient outcomes looks increasingly promising.
Disclaimer: The preceding article is based on a business announcement and should not replace professional financial advice. Always consult with a financial advisor before making any investment decisions.
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.
Verified Sources: